Assistant Member
Department of Cancer Chemoprevention
Roswell Park Cancer Institute

Professor
Recent Advances in Pathology, PhD Program
Department of Cancer Pathology and Prevention
State University of New York at Buffalo

Dr. Yan Dong, PhD, joined the staff of Roswell Park Cancer Institute (RPCI) in 1994 while completing her PhD and now serves as an Assistant Member and Professor of the Department of Cancer Chemoprevention.

Dr. Dong earned her doctoral degree from the State University of New York at Buffalo in Experimental Pathology in 2000. She also earned her Masters in Molecular Biology from the Chinese Academy of Sciences, Beijing, P.R. China in 1994 and her Bachelor’s in Molecular Biology from Jilin University, Changchun, Jilin, P.R. China in 1992.

Dr. Dong’s research interests include selenium chemoprevention in relation to prostate cancer and selenium sensitization of chemotherapy or hormonal therapy in relation to prostate and breast cancer.

Dr. Dong is a member of the American Association of Cancer Research and Women in Cancer Research, a division of the American Association of Cancer Research.

Dr. Dong has been awarded a number of different grants including the American Cancer Society Research Grant which commences in July 2007 and will be completed in June of 2011, the National Cancer Institute Howard Temin Career Development Award between June 2005 and May 2010, the Department of Defense New Investigator Award between February 2004 and January 2007, and the Jilin Provincial Scholarship for Outstanding Scientists between February 2007 and January 2009.

Dr. Dong has authored or coauthored over 27 journal articles and book chapters.

Selected Publications

• Dong Y, Zhang H, Gao AC, Marshall JR, Ip C. Androgen receptor signaling intensity is a key factor in determining the sensitivity of prostate cancer cells to selenium inhibition of growth and cancer-specific biomarkers. Molecular Cancer Therapeutics, 2005; 4: 1047-1055.
• Ip, C, Marshall JR, Park Y-M, Zhang H, Dong Y, Wu Y, Gao AC. Selenium and Cancer Prevention. Chapter in Nutritional Oncology, 2nd ed. Academic Press 2006; 573-581.
• Lee SO, Chun JY, Nadiminty N, Trump DL, Ip C, Dong Y, Gao AC. Monomethylated selenium inhibits growth of LNCaP human prostate cancer xenograft accompanied by a decrease in the expression of androgen receptor and prostate-specific antigen (PSA). Prostate 2006; 66:1070-1075.
• Zhang H, Wu Y, Malewicz B, Lu J, Li S, Marshall J, Ip C, Dong Y. Augmented Suppression of Androgen Receptor Signaling by a Combination of a-Tocopheryl Succinate and Methylseleninic Acid. Cancer 2006; 107:2942-2948.
• Lee SO, Chun JY, Nadiminty N, Trump DL, Ip C, Dong Y, Gao AC. Monomethylated selenium inhibits growth of LNCaP human prostate cancer xenograft accompanied by a decrease in the expression of androgen receptor and prostate-specific antigen (PSA). Prostate 2006; 66(10):1070-1075
• Li S, Zhou Y, Wang R, Zhang H, Dong Y, Ip C. Selenium Sensitizes MCF-7 Breast Cancer Cells to Doxorubicin-induced Apoptosis through Modulation of Phospho-Akt and Its Downstream Substrates. Molecular Cancer Therapeutics 2007; 6:1031-1038.
• Liu S, Zhao L, Zhang H, Dong Y. KLF4 is a novel mediator of selenium in growth inhibition. Molecular Cancer Research, accepted with minor revision, 2007.